A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...
A replay of the webcast Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for ...
Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research ...
The oncology business, meanwhile, would be biologics-focused and feature lead drug nemvaleukin alfa – an IL-2 therapy in phase 3 testing alongside Merck & Co's Keytruda (pembrolizumab ...
With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
Relacorilant plus nab-paclitaxel chemotherapy reduced the risk of disease progression by 30% compared with nab-paclitaxel alone. Treatment with relacorilant plus nab-paclitaxel improved ...
Mural Oncology plc announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck's (known as MSD outside the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback